Akebia Therapeutics (AKBA) PT Raised to $6, Piper Sandler 'Buyers on Weakness'
Tweet Send to a Friend
Piper Sandler analyst Allison M. Bratzel raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $6.00 (from $4.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
